LOREA _ ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF LORLATINIB IN UNTREATED ALK-POSITIVE NSCLC PATIENTS IN A FRENCH REAL-WORLD CONTEXT

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000000111
• Study ID:
  1000000111
• Official title and acronym:
  LOREA _ ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF LORLATINIB IN UNTREATED ALK-POSITIVE NSCLC PATIENTS IN A FRENCH REAL-WORLD CONTEXT
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  This study is a national prospective cohort that aims to analyse the effectiveness and safety of lorlatinib in a real-world setting. More precisely, the study aims at understanding the reasons why some patients should switch from lorlatinib to another treatment, being due to disease progression or toxicity, and reduce attrition rate.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Pfizer

Networks

Cleanweb

Study timelines

Date when funding contract was signed

Planned:31/01/2024

Actual:31/01/2024

Study start date

Planned:09/04/2024

Actual:09/04/2024

Date of final study report

Planned:31/01/2029

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

B7461051 : internal ID number
EUDRACT number : 2024-A00637-40